Venlafaxine Caffeic Acid Salt: Synthesis, Structural Characterization, and Hypoglycemic Effect Analysis.

Area of Science:

• Pharmaceutical Sciences
• Medicinal Chemistry
• Clinical Pharmacy

Background:

• Major depressive disorder (MDD) affects 15-20% of diabetic patients and is an independent risk factor for type 2 diabetes.
• Depression can exacerbate hyperglycemia and accelerate diabetic complications.
• Venlafaxine, a common antidepressant, is poorly soluble and its overdose may cause hypoglycemia.

Purpose of the Study:

• To improve the physicochemical and pharmacokinetic properties of venlafaxine.
• To develop a novel crystalline salt of venlafaxine with enhanced solubility and therapeutic potential.
• To evaluate the hypoglycemic activity of the new venlafaxine-caffeic acid salt.

Main Methods:

• Crystalline venlafaxine-caffeic acid (1:1) salt synthesized using solvent evaporation, slurry, and liquid-assisted grinding methods.
• Solid-state characterization using powder X-ray diffraction, DSC, TGA, FTIR, and solid-state NMR.
• Crystal structure determination via single-crystal X-ray diffraction.
• Comparative analysis of solubility, dissolution, and in vitro hypoglycemic activity.

Main Results:

• The venlafaxine-caffeic acid salt exhibited approximately 16-fold higher solubility compared to venlafaxine.
• The novel salt demonstrated potent in vitro hypoglycemic activity in glucose consumption assays.
• Solid-state characterization confirmed the crystalline nature and structure of the salt.

Conclusions:

• Venlafaxine-caffeic acid salt formation significantly enhances venlafaxine solubility and dissolution.
• The novel salt possesses promising in vitro hypoglycemic activity, suggesting therapeutic potential.
• This new salt is a promising candidate for treating major depressive disorder in patients with type 2 diabetes.